Overview

* Trevi Therapeutics' ( TRVI ) Q3 net loss narrows to $11.8 mln from $13.2 mln in 2024

* Company preparing to initiate Phase 3 program for chronic cough in IPF in 2026

* Trevi ends Q3 with $194.9 mln in cash, runway expected into 2028

Outlook

* Company plans to initiate Phase 3 program for chronic cough in IPF in H1 2026

* Trevi expects cash runway to last into 2028

* Company plans to start Phase 2b RCC study in first half of 2026

Result Drivers

* OTHER INCOME - Increased to $2.1 mln from $0.8 mln due to interest income from higher invested cash equivalent and marketable securities balances

* R&D EXPENSES - Fell by $1.1 mln

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.08

Q3 Net -$11.80

Income mln

Q3 -$13.92

Income mln

from

Operatio

ns

Q3 $13.92

Operatin mln

g

Expenses

Q3 -$11.82

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Trevi Therapeutics Inc ( TRVI ) is $20.00, about 40.8% above its November 12 closing price of $11.85

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)